Patients undergoing PCa treatment must be aware that PAEs can interfere with therapeutic efficacy; for instance, DBP may promote tumor progression by competitively binding to the AR or activating ERα, potentially undermining androgen deprivation therapy (ADT) (Zhang T. et al., 2021). This evidence concerns the gene ESR1 and posterior cortical atrophy.